postMONARCH III期试验:阿贝西利联合氟维司群用于CDK4/6i经治HR+/HER2-晚期乳腺癌的最终总生存分析
postMONARCH III期试验纳入368例既往CDK4/6i联合内分泌治疗进展的HR+/HER2-晚期乳腺癌患者,1:1随机接受阿贝西利联合氟维司群或安慰剂联合氟维司群。预设最终OS分析显示,阿贝西利组中位OS为32.1个月,对照组为24.6个月(HR 0.80,95%CI 0.60-1.06,P=0.11),未达到统计学显著性边界。更新PFS与主要分析一致(HR 0.78,95%CI 0.62-0.99,名义P=0.039)。
要点
- 阿贝西利联合氟维司群中位OS数值上优于对照组(32.1 vs 24.6个月),但未达统计学显著。
- 更新PFS HR 0.78(95%CI 0.62-0.99),与主要分析一致。
- 安全性无新信号,支持CDK4/6i经治后考虑含阿贝西利方案。
核心结论
- 阿贝西利联合氟维司群较安慰剂联合氟维司群在HR+/HER2-晚期乳腺癌CDK4/6i经治患者中显示中位OS数值延长,但未达到预设统计学显著性边界。
研究设计与样本
- III期postMONARCH试验,368例既往CDK4/6i联合内分泌治疗进展的HR+/HER2-晚期乳腺癌患者1:1随机接受阿贝西利联合氟维司群(n=182)或安慰剂联合氟维司群(n=186)。
主要发现
- 数据截止时中位随访约37个月,共观察到200例OS事件(阿贝西利组90例[50%],对照组110例[59%])。
- 阿贝西利联合氟维司群中位OS为32.1个月,安慰剂联合氟维司群为24.6个月(HR 0.80,95%CI 0.60-1.06,P=0.11),未达到显著性边界。
- OS差异在各亚组中一致。
- 更新PFS与主要分析一致(HR 0.78,95%CI 0.62-0.99,名义P=0.039)。
- 至第二次进展时间和无化疗生存期也倾向于阿贝西利联合氟维司群。
关键数值与推荐
- 最终OS分析预设于200例OS事件时进行,HR显著性边界为0.753。
- 安全性特征与阿贝西利已知概况一致,未发现新信号。
临床怎么用
- 对于既往CDK4/6i联合内分泌治疗进展的HR+/HER2-晚期乳腺癌患者,现有证据总体支持考虑含阿贝西利的治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III postMONARCH trial demonstrated a statistically significant improvement in progression-free survival (PFS) with abemaciclib plus fulvestrant versus placebo plus fulvestrant in participants with HR+, HER2- advanced breast cancer (ABC) after disease progression on prior CDK4/6i plus endocrine therapy (ET). Here we report the prespecified final overall survival (OS) analysis. PARTICIPANTS AND METHODS: Eligible patients had disease progression on a CDK4/6i plus aromatase inhibitor as initial therapy for ABC or recurrence on or after adjuvant CDK4/6i plus ET. Participants were randomly assigned 1:1 to receive abemaciclib plus fulvestrant or placebo plus fulvestrant. The final OS analysis was pre-specified at 200 OS events (HR boundary 0.753). Time-to-event analyses used the Kaplan-Meier method, and stratified Cox models were used to estimate the HR and 95% confidence intervals (CI). RESULTS: A total of 368 participants were randomly assigned 1:1 to abemaciclib plus fulvestrant (n = 182) or placebo plus fulvestrant (n = 186). At data cutoff, median follow-up was approximately 37 months; 200 OS events were observed (90 [50%] vs 110 [59%]). Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR, 0.80 [95% CI, 0.60 to 1.06]; P = 0.11, boundary for significance not reached). OS differences were consistent across subgroups. Updated PFS was consistent with the primary analysis (HR, 0.78 [95% CI, 0.62 to 0.99]; nominal P = 0.039). Time to second progression and chemotherapy-free survival also favored abemaciclib plus fulvestrant. Safety was consistent with the established abemaciclib profile with no new signals identified. CONCLUSION: Abemaciclib plus fulvestrant resulted in numerically longer median OS versus placebo plus fulvestrant, though statistical significance was not reached. The totality of evidence supports consideration of abemaciclib-based treatment for patients with HR+, HER2- ABC after disease progression on prior CDK4/6i plus ET. CLINICAL TRIAL REGISTRATION NUMBER: NCT05169567.
引用
- Kalinsky K, Wander SA, Hamilton E, et al. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026. PMID: 42926108. doi:10.1016/j.annonc.2026.10.1283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。